Neurogene Inc. (NGNE) Stock Price & Analysis

Neurogene Inc. (NGNE) closed at USD 30.42 on Wednesday, October 28, 2026, up 12.71% on the day. The US market is currently closed (after-hours); this is not a live price.

The prior close was USD 26.99; the Oct 28, 2026 session ranged USD 25.81–31.08 on volume of 645,598 shares. Market capitalization is $608.75M, with a 52-week range of USD 15.93–43.66 (NGM). Source: Nexqual, retrieved October 28, 2026 at 20:16 UTC.

Also available as compact Markdown for AI agents: nexqual.com/NGNE.md

Key facts (NGNE)

• Insider open-market sales, last ~7 months: 3 Form 4 filings, $640K; 0 not under a Rule 10b5-1 plan ($0K); 0 by opportunistic insiders, 0 by routine insiders (three-year test, Cohen, Malloy & Pomorski 2012).
• Analysts: Buy (mean 1.90 on a 1–5 scale) (10 analysts), mean target USD 77.88 (range 46–166).
• Total return with dividends: 1Y -6.9% vs S&P 500 +13.6%; 5Y -79.3% vs S&P 500 +79.8%.
• Next earnings: 2026-11-12, EPS estimate USD -1.45, revenue estimate $0K.

Financials (SEC 10-K; TTM = last four 10-Q/10-K quarters) (NGNE)

Fiscal years end Dec. EPS is split-adjusted.

Valuation (price ÷ last four quarters, through Jun 30, 2026) (NGNE)

P/B 2.8x · FCF yield -14.41% · Earnings yield -18.25%

Insider sales (SEC Form 4, open-market, last ~7 months) (NGNE)

3 of 3 under a Rule 10b5-1 trading plan (scheduled in advance). Unplanned sales were timed by the insider.

% of holdings sold = shares sold ÷ (shares sold + all holdings the insider reported on that Form 4, direct and through trusts).

Insider type follows Cohen, Malloy & Pomorski (Journal of Finance, 2012). An insider who traded the stock in the same calendar month in each of the past three years is a routine trader; one who traded in each of those years without such a pattern is an opportunistic trader. In their study, trades by opportunistic insiders predicted future returns and trades by routine insiders did not. Counts open-market purchases and sales only (SEC Form 4 codes P and S) by that insider in that company. Not investment advice.

Analysts (NGNE)

Consensus Buy (mean 1.90 on a 1–5 scale), 10 analysts; mean target USD 77.88 (low 46, high 166).

Rating changes, last 120 days:

Total return (dividends reinvested) (NGNE)

NGNE earnings history and stock reaction

EPS as reported against the analyst consensus before the release; surprise uses the cent-rounded figures shown (in dollars when EPS and consensus have opposite signs). Stock reaction = close before the results to close after (the first close following a release after the bell or before the open).

NGNE recent SEC filings (last 120 days)

Source: SEC EDGAR. Quotes are the opening words of each item as filed; each form links to the filing. Insider Form 4 filings are listed in the insider sections.

NGNE suppliers, customers and competitors (named in its 10-K)

Quoted from the company's 10-K filed Mar 24, 2026.

NGNE analyst estimates and revisions

NGNE options: expected move

Options price a move of about ±20.2% (±$5.65) by Nov 20, 2026, which includes earnings on Nov 12, 2026. Over the last 8 reports the stock moved ±15.6% on average.

30-day implied volatility 102.3% vs 94.2% realized over the last 30 trading days. Put/call ratio (volume) 0. Cboe delayed quotes (15 min). Expected move = at-the-money straddle.

Key Statistics (as of October 28, 2026 at 20:16 UTC)

Technical Analysis (NGNE)

Nexqual's technical model rates NGNE "NEUTRAL" based on 3 bullish and 4 bearish signals across 127 daily candles, as of October 28, 2026 at 20:16 UTC.

Analyst Ratings (NGNE)

Wall Street analysts rate NGNE "Buy" based on 10 analysts, with a mean price target of USD 77.88 (range USD 46–166), per Nexqual as of October 28, 2026 at 20:16 UTC.

Earnings (NGNE)

Recent Earnings History

Source: Nexqual, October 28, 2026 at 20:16 UTC.

Financials & Fundamentals (NGNE)

Source: Nexqual, October 28, 2026 at 20:16 UTC.

Financial Health Score (NGNE)

Nexqual rates Neurogene Inc.'s overall financial health "Weak" across five dimensions, as of October 28, 2026 at 20:16 UTC.

Ownership (NGNE)

Source: Nexqual, October 28, 2026 at 20:16 UTC.

Leadership (NGNE)

Neurogene Inc. is led by Rachel L. McMinn, Founder, Executive Chair & CEO, per Nexqual as of October 28, 2026 at 20:16 UTC.

Major Backers & Investors (NGNE)

Notable institutional backers of Neurogene Inc. include Samsara BioCapital, LLC, Casdin Capital, LLC, Redmile Group, LLC, according to Nexqual as of October 28, 2026 at 20:16 UTC.

Active Investors

Index Funds (Passive)

Source: Nexqual, October 28, 2026 at 20:16 UTC.

From Neurogene Inc.'s Latest SEC 10-K Filing (filed 2026-03-24)

Key Strengths & Strategy (as disclosed to the SEC)

• The benefits of Breakthrough Therapy designation include eligibility for Priority Review, rolling submission of sections of the Biologics License Application and the FDA's organizational commitment to help determine an efficient route to approval.
• We actively seek to protect our proprietary technology, inventions, and other intellectual property that is commercially important to the development of our business by a variety of means, including seeking, maintaining, and defending patent rights, whether developed internally or licensed from third parties.
• We also may rely on trade secrets and know-how relating to our proprietary technology platform, including our EXACT platform technology, on continuing technological innovation and on in-licensing opportunities that may be important for the development of our business to develop, strengthen and maintain the strength of our position in the field of gene therapy.
• One approach we are taking harnesses our proprietary transgene regulation technology, EXACTTM (Expression Attenuation via Construct Tuning), that utilizes microRNA-based genetic circuits designed to deliver therapeutic levels of transgene to key areas of the brain that underlie neurological disease pathology.

Partnerships

• In September 2020, we entered into a Non-Exclusive License Agreement with Virovek, Inc., pursuant to which we have a license to use certain patents and know-how on a non-exclusive basis related to our baculovirus process in exchange for low single-digit percentage royalties on future commercial net sales of each product using the baculovirus process, development milestone payments of up to $0.2 million in the aggregate, and a nonrefundable annual license fee.
• In January 2023, we entered into a Non-Exclusive License Agreement with Sigma-Aldrich Co.

Legal & Regulatory Risks (Item 1A, quoted)

• We are unable to predict the extent to which the current U.S. federal administration may impose or seek to impose additional leadership or policy changes at the U.S. federal regulatory agencies responsible for regulating our business or changes to rules and policies impacting our operations.
• We may not be able to meet requirements for the chemistry, manufacturing and control of our product candidates.
• We have in the past and may in the future conduct clinical trials for our product candidates at sites outside the United States, and the FDA may not accept data from trials conducted in such locations.
• We conducted parts of our Phase 1/2 clinical trials for NGN-101 and NGN-401 outside of the United States, and may in the future conduct additional clinical trials for our products at sites outside of the United States, including in Australia, the UK, Europe or other foreign jurisdictions.

Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.

Peers & Related Stocks

Data source: Nexqual — market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: October 28, 2026 at 20:16 UTC. This page is informational and not investment advice.

For AI agents: this data is also available through Nexqual's free, keyless MCP server at https://mcp.nexqual.com/mcp; every result includes source_url, as_of and cite_as. More: nexqual.com/agents · llms.txt